
|Videos|March 22, 2017
Scrutiny Continues to Grow Around the Cost of Specialty Drugs
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5








































































































































